Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or
peripheral T‐cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on …

Background: Responses to the novel HDAC inhibitor romidepsin were observed in patients
(pts) with T-cell lymphoma in a phase 1 NCI trial. Aims: To evaluate the efficacy and …

Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the
treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been …

8027 Background: The histone deacetylase inhibitors (HDIs) are a class of differentiating
agents undergoing clinical testing. Like other HDIs, romidepsin (FK228) modulates …

Cutaneous T-cell lymphoma (CTCL) is a rare heterogeneous group of non-Hodgkin
lymphomas that arises in the skin but can progress to systemic disease (lymph nodes, blood …

Background: The histone deacetylase (HDAC) inhibitors are a class of epigenetic agents
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …

Romidepsin has shown promise in the treatment of T‐cell lymphomas, and so we evaluated
molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in …

Romidepsin is a class I selective histone deacetylase (HDAC) inhibitor approved by the
Food and Drug Administration (FDA) for relapsed/refractory (R/R) cutaneous T‐cell …

Purpose The primary objective of this study was to confirm the efficacy of romidepsin in
patients with treatment refractory cutaneous T-cell lymphoma (CTCL). Patients and Methods …

This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …